Novartis has entered into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics, bolstering its gene therapy portfolio.

Researchers in the School of Veterinary Medicine and colleagues have developed a gene therapy that restores dim-light vision in dogs with a congenital form of night blindness, offering hope for treating a similar condition in people.

An international team of health researchers have, for the first time, described how genetic defects influence the spectrum of vision development and cause problems in developing babies' eyes.